S63845 is a small molecule that inhibits antiapoptosis protein myeloid cell leukemia 1 (MCL1) and potently kills MCL1‐dependent cancer cells[27] and synergistically (plus Navitoclax) kills difficult‐to‐treat melanoma cells.[28] S63845/S64315 (MIK665) are currently under clinical trials (clinical trials.gov; NCT03672695; NCT01989585). Here, MCL1 is linked to melanoma.